Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.
1 other identifier
interventional
20
0 countries
N/A
Brief Summary
The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug. The main questions it aims to answer are: Can the drug cause repigmentation of vitiligo lesions when used as topical form after microneedling? What medical problems do participants have when the drug used? Participants will: Visit the clinic once every 2 weeks to have the microneedling sessions for 3 months. and also they will have narrow band UVB sessions two times per week. Record any side effect they have during or after the sessions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 20, 2025
CompletedFirst Posted
Study publicly available on registry
July 28, 2025
CompletedStudy Start
First participant enrolled
August 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
ExpectedJuly 30, 2025
July 1, 2025
7 months
July 20, 2025
July 25, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Repigmentation of vitiligo lesions
The repigmentation responses will be expressed qualitatively as the following No change (0%-25%) = mild improvement (26%-50%) = moderate improvement (51%-75%) = good improvement (76%-100%) = excellent improvement
3 months from the start of treatment
Study Arms (1)
the main patch with microneedling and topical crisaborole and two patches as control
OTHEReach patient will have 3 vitiligo patches one will be treated by microneedling and topical application of crisaborole and the other 2 patches will be considered as control patches
Interventions
From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions
Eligibility Criteria
You may qualify if:
- Patients suffer from non-segmental stable vitiligo.
- Patients who will accept to be included in the study and will sign a written consent.
You may not qualify if:
- Patients with history of koebnerization or any sign of disease activity.
- Patients with keloid tendency.
- Patients with active infection.
- Pregnant or lactating woman.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tanta Universitylead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of Dermatology and Venereology
Study Record Dates
First Submitted
July 20, 2025
First Posted
July 28, 2025
Study Start
August 1, 2025
Primary Completion
March 1, 2026
Study Completion (Estimated)
August 1, 2026
Last Updated
July 30, 2025
Record last verified: 2025-07